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Original Investigation | EmergencyMedicine
Incidence of Pediatric Cannabis Exposure Among
Children and Teenagers Aged 0 to 19 Years Before and After
Medical Marijuana Legalization inMassachusetts
Jennifer M.Whitehill, PhD; Calla Harrington, MSW,MPH; Cheryl J. Lang, MPH; Michael Chary, MD, PhD;Waqaas A. Bhutta, MBA, MPH; Michele M. Burns, MD, MPH
Abstract
IMPORTANCE Pediatric health care contacts due to cannabis exposure increased in Colorado and
Washington State after cannabis (marijuana) policies becamemore liberal, but evidence from other
US states is limited.
OBJECTIVE To document the incidence of pediatric cannabis exposure cases reported to the
Regional Center for Poison Control and Prevention (RPC) before and after medical marijuana
legalization (MML) in Massachusetts.
DESIGN, SETTING, ANDPARTICIPANTS Cross-sectional comparison of pediatric cannabis
exposure cases 4 years before and after MML in Massachusetts. The exposure cases included those
of 218 children and teenagers aged between 0 and 19 years, as reported to the RPC from 2009 to
2016. Census data were used to determine the incidence. Data analysis was performed from
November 12, 2018, to July 20, 2019.
EXPOSURE Cannabis products.
MAINOUTCOMESANDMEASURES Incidence of RPC-reported cannabis exposure cases, both
single substance and polysubstance, for the age group of 0 to 19 years, and cannabis product type,
coingestants, and clinical effects.
RESULTS During the 8-year study period (2009-2016), the RPC received 218 calls involving
cannabis exposure (98 single substance, 120 polysubstance) in children and teenagers aged 0 to 19
years, representing 0.15% of all RPC calls in that age group for that period. Of the total exposure
cases, males accounted for 132 (60.6%) and females 86 (39.4%). The incidence of single-substance
cannabis calls increased from0.4 per 100000population beforeMML to 1.1 per 100000population
after (incidence rate ratio, 2.4; 95%CI, 1.5-3.9), a 140% increase. The age group of 15 to 19 years had
the highest frequency of RPC-reported cannabis exposures (178 calls [81.7%]). The proportion of all
RPC calls due to single-substance cannabis exposure increased overall for all age groups from 29
before MML to 69 afterward. Exposure to edible products increased after MML for most age groups.
CONCLUSIONS ANDRELEVANCE Pediatric cannabis exposure cases increased inMassachusetts
after medical marijuana was legalized in 2012, despite using childproof packaging andwarning labels.
This study provides additional evidence suggesting that MMLmay be associated with an increase in
cannabis exposure cases among very young children, and extends prior work showing that teenagers
are also experiencing increased cannabis-related health system contacts via the RPC. Additional
efforts are needed to keep higher-potency edible products and concentrated extracts from children
(continued)
Key Points
Question Does the number of pediatric
cannabis (marijuana) exposure cases
before medical marijuana legalization in
Massachusetts differ from the number
afterward?
Findings In this repeated cross-
sectional study, there were 218 calls
related to cannabis exposure received
by the Regional Center for Poison
Control and Prevention in
Massachusetts, constituting 0.15% of all
calls concerning children and teenagers
aged 0 to 19 years. The number of calls
regarding single-substance cannabis
exposure, especially edible product
exposure, in this age group showed a
statistically significant increase; the
number of such calls for all cannabis
product types more than doubled from
29 calls 4 years before MML to 69 calls 4
year afterwards.
Meaning This study suggests that
states liberalizing marijuana policies
should consider strengthening
regulations to prevent unintentional
exposure among young children and
enhancing efforts to prevent use by
teenagers, with particular attention to
edible cannabis products and
concentrated extracts.
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(8):e199456. doi:10.1001/jamanetworkopen.2019.9456 (Reprinted) August 16, 2019 1/10
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts Amherst User  on 08/23/2019
Abstract (continued)
and teenagers, especially considering theMML and retail cannabis sales in an increasing number of
US states.
JAMA Network Open. 2019;2(8):e199456. doi:10.1001/jamanetworkopen.2019.9456
Introduction
Cannabis (marijuana) has been legalized for medical use in 33 US states and for adult use (ie,
recreational use) in 11 as of July 2019.1 Evidence from the first US states to liberalize and
commercialize cannabis suggests that such legalization policies may lead to unintended
consequences for youth including increase in poisoning from unintentional or intentional
exposure.2,3
For young children aged 0 to 9 years, unintentional exposure to cannabis owned or used by
other members of the household is of concern. Data from Colorado andWashington State indicate
that, for children aged 0 to 9 years, the number of cannabis-related calls to the regional poison
center increased as commercial medical marijuana dispensaries proliferated4 and after cannabis use
was legalized for general adult (recreational) purposes.5-7 Edible cannabis products were involved
in nearly half of the cases with a known product type.5,7,8
For older children and teenagers aged 10 to 19 years, acute illness or severe psychological
effects related to intentional cannabis usemay result in a health care contact. Adolescent urgent care
and emergency department visits related to cannabis increased in Colorado between 2005 and 2015
as cannabis laws becamemore permissive9 despite the fact that population surveys generally have
not found increases in the prevalence of adolescent cannabis use.10,11 Most prior research onmedical
marijuana policies and pediatric exposures has been conducted in the western United States, which
may have different cultural and policy environments compared to other regions.
Massachusetts voters passedmedical marijuana legalization (MML) by ballot initiative in 2012
and the first dispensaries opened in 2015. Medical marijuana was initially regulated by the
Massachusetts Department of Public Health, which imposed strict requirements for childproof
packaging, warning labels, and dosage information, and prohibited themanufactured edible
products from resembling commercially available candy.12 These regulations were generally more
restrictive than those passed in the first states to commercialize medical marijuana. In December
2018, oversight was transferred to the Cannabis Control Commission, a new state agency. Although
medical marijuana is primarily used by adults, it is available for patients younger than 18 years if
diagnosed with a debilitating, life-limiting illness or condition for which benefits outweigh potential
risks as determined by 2 Massachusetts-licensed, certifying physicians.13 Patients receiving medical
marijuana are able to receive up to a 60-day supply ofmarijuana at a time, defined as 283.5 g of dry
flower or 42.5 g of cannabis concentrates or resin.13 This amount is a potentially greater quantity than
allowed in other states, which generally have 28- to 56-g limits.14,15
The purpose of this study was to compare cannabis exposure calls for children and teenagers
aged 0 to 19 years received by the Regional Center for Poison Control and Prevention (RPC) for 4
years before and after MML in Massachusetts. Specifically, we sought to (1) describe the incidence of
single-substance and polysubstance cannabis-involved exposures for children and teenagers; (2)
examine whether cannabis-related calls increased as a proportion of all RPC calls; and (3) assess
patterns in product formulations involved in RPC-reported cases. Understanding and learning from
trends in cannabis exposures and coexposures after MML was implemented can have implications
for policy makers in states now implementing medical or nonmedical marijuana legalization.
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Methods
This study followed the Strengthening theReporting ofObservational Studies in Epidemiology (STROBE)
reporting guideline. For this cross-sectional study, we obtained data on all Massachusetts cannabis
exposure cases reported to theMassachusetts and Rhode Island RPC between January 1, 2009, and
December 31, 2016.We focused on the pediatric age range of 0 to 19 years, excluding cases of unknown
age. Datawere obtained from the RPC’s local installation of the American Association of Poison Control
Centers’ data warehouse, the National Poison Data System (NPDS). The RPC staff reviewed the cases,
and only deidentified data were shared with external collaborators. The study received an exempt
determination from the institutional reviewboard at Boston Children’s Hospital, Boston,Massachusetts,
owing to the use of deidentified patient data.
Data analysis was performed fromNovember 12, 2018, to July 20, 2019. Data included age, sex,
route of exposure (inhalation/nasal, ingestion, rectal, multiple routes, or unknown), caller location
(health care facility, own residence, school, or other), exposure site (own residence, other residence,
school, or unknown), medical outcome, and intent. Medical outcomes were classified using the
published NPDS definitions (death; major effect; moderate effect; no effect; unable to follow, judged
as potentially toxic exposure; not followed, judged as nontoxic exposure; not followed, minimal
clinical effects possible; or unrelated effect).16 For reporting, we combined the latter 3 categories into
1 category for cases not followed, with minimal or unrelated effects. Intent was classified into 8
categories that were grouped as intentional (abuse andmisuse, suspected suicide, or unknown
intentional), unintentional, other (malicious or contamination/sampling), adverse drug reaction, or
unknown. The RPC also provided aggregate numbers of all poisoning exposure calls inMassachusetts
by age group and year.
Cannabis-related cases were identified using the product code based on the NPDS. We
classified these product codes into the following 4 categories: plant, edible preparations,
concentrated extracts, and other. The plant category included codes for generic marijuana dried
plants (code 083000) as well as undried plants (310123). The code for edible preparation (310121)
constituted its own category. To include oils, tinctures, and vaping products, which we classified
under concentrated extracts, we included specific marijuana product codes for the following
subcategories: concentrated extracts, including oils and tinctures (code 310124); marijuana device
with added flavor (310034), without added flavor (310033), and flavor unknown (310096); as well
as electronic cigarettes (e-cigarettes): marijuana liquid with added flavors (310036), without added
flavors (310035), and flavor unknown (310097). Other marijuana product codes included the
following: marijuana oral capsule or pill preparation (code 310122), marijuana other or unknown
preparation (310126), marijuana pharmaceutical preparation (200618), andmarijuana topical
preparation (310125).
Marijuana codes have changed in the NPDS over time in ways relevant to this analysis. The
generic marijuana code for dried plant material (code 083000) was the first marijuana code in the
NPDS and was activated in 1985. A code for pharmaceutical preparation (200618) was activated in
2010. Codes related to marijuana vaping (e-cigarette) products (310096, 310034, 310033, 310097,
310036, and 310035) were added in 2014. In 2016, codes were added for marijuana concentrated
extract (310124), edible preparation (310121), oral capsules or pill preparation (310122), topical
preparation (310125), undried plant (310123), and other or unknown preparation (310126). Two of us
(C.J.L. andW.A.B.) recoded data for 2009 to 2016 into the newer codes to allow analysis by product
type for the time before these codes were used. The procedures were discussed with a specialist in
poison information—one of the trained clinicians who answer calls to the RPC—to ensure that the
coding would be consistent with current coding practices when fielding calls. For example, the
authors reviewed case notes from cases previously coded as generic marijuana (083000); if the case
notes referred to a cannabis exposure from an edible form ofmarijuana, they recoded the data using
the new code for edible preparation (310121). Ambiguous cases were rare and were discussed with
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the RPCmedical director (M.M.B.). Plant-related cases generally involved dried plant material with 2
cases of exposure to undried plants.
To determine whether cannabis exposure substantially contributed to themajor clinical
outcomes for each case, a group of 3 medical toxicologists independently reviewed each case. Inter-
rater agreement was quantified by the Cohen κ, with a value of 0.49. Guidelines for defining major
clinical outcomes were formulated based on a 10% random sample, which was not used for
subsequent calculations of agreement. We considered a reported cannabis ingestion to be clinically
significant if the symptoms that warranted medical intervention or evaluation were more consistent
with the known effects of cannabis than any other substances reported to be ingested. For example,
we did not consider the ingestion of cannabis to be clinically significant in a patient presenting with
somnolence and conjunctival injection and reported cannabis and alcohol ingestion. Although
conjunctival injection is consistent with cannabis ingestion, the somnolence is the clinically
significant factor and is more likely due to alcohol ingestion. In contrast, we considered the ingestion
of cannabis to be clinically significant in a patient presenting with paranoia and reported ingestion
of marijuana and alcohol.
Statistical Analysis
Cases were separated into 2 categories: single-substance cannabis exposures (ie, cannabis was the
only substance involved) and polysubstance cases (ie, cannabis was one of several substances). The
medical marijuana law took effect inMassachusetts on January 1, 2013, so the proportion of all calls
to the RPC involving cannabis only or cannabis plus other substances was assessed for statistical
significance before (2009-2012) vs after (2013-2016) MML.
We stratified the analyses by age group (0-4, 5-9, 10-14, and 15-19 years). The incidence was
calculated by dividing the number of single-substance and polysubstance cases by the number of
person-years contributed by all individuals in theMassachusetts population during the time period
(4 years pre-MML and 4 years post-MML) andmultiplying by 100000. Population estimates by age
were obtained from the US Census data for 2009 to 2016.17,18 We computed and compared the
incidence rate ratios (IRRs) before vs after MMLwith 95% CIs. We also compared the proportion of
all RPC calls that were related to cannabis before vs after MML. We stratified single-substance
cannabis cases by formulation and compared each age group’s number and proportion of
RPC-reported cases of each product type before vs after MML. For comparisons of proportions,
Fisher exact tests were used when cells in the 2 × 2 table had 5 or fewer cases; otherwise, χ2 tests
were used. All statistical analyses were performed using Stata software, version 15 (StataCorp LP).
The significance threshold was α = .05, and all testing was 2-sided.
Results
During the 8-year study (2009-2016), a total of 218 calls received by the RPCwere related to
cannabis exposure among children and teenagers aged 0 to 19 years, representing 0.15% of all RPC
calls in that age group for that period. The age group of 15 to 19 years had the highest frequency of
RPC-reported cannabis exposures (178 calls [81.7%]). Of the 218 exposure cases, males accounted
for 132 (60.6%) and females 86 (39.4%). Males accounted for 51 of the 98 single-substance cannabis
cases (52.0%) and 81 of the 120 polysubstance cases (67.5%) (Table 1). Teenagers aged 15 to 19 years
were involved in the highest number of cases, accounting for 69 cannabis-only exposures (70.4%)
and 109 polysubstance exposures (90.8%). The youngest children, aged 0 to 4 years, accounted for
19 single-substance cannabis cases (19.4%) and 3 polysubstance cases (2.5%).
Inhalation or nasal exposure was the most common route and was observed in 50 single-
substance cannabis cases (51.0%) and 103 polysubstance cases (85.8%). An additional 46 cannabis-
only cases (46.9%) resulted from ingestion. Approximately two-thirds of the single-substance
cannabis cases (65 [66.3%]) and 111 polysubstance cases (92.5%) were classified as intentional
exposures. Among the cases involving children aged 0 to 4 years, most (19 [86.4%]) were due to
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ingestion (eTable in the Supplement), whereas for teenagers aged 15 to 19 years, 140 cases (78.7%)
were related to inhalation. Most calls (172 [78.9%]) were received from health care facilities and 37
(17.0%) from the caller’s own residence (eTable in the Supplement).
Moderate andminor effects were themost commonmedical outcomes reported by RPC
professionals, constituting 154 cases (70.6%) (Table 1). No deaths were reported. A higher
proportion of cases (3 [2.5%]) was observed involving a major effect for polysubstance cases (as
many as 8 substances involved) compared with cases involving only cannabis. The single RPC call for
amajor effect from single-substance cannabis exposure involved 2 unrelated adolescentmales (aged
17 and 18 years) with no known health problems who collapsed while playing sports, hours after
smoking what they believed to bemarijuana. There was no report of intentional ingestion of
“syntheticmarijuana.” Theywere found to be in cardiac arrest and successfully resuscitated. A sample
of the substance they used was not available for analysis. This case suggests the possibility of
contaminatedmarijuana as the cause of the clinical effects.
For polysubstance cases, the following were themost frequently coingested substances were
alcohol (26%); 3,4-methylenedioxy-methamphetamine (MDMA/ecstasy) (11%); preparations
containing dextromethorphan (9%); benzodiazepines (8%); and crack/cocaine (5%). Of the 120
cases, medical toxicologists classified 85 (71%) as cases where cannabis ingestion likely had clinical
Table 1. Cannabis-Related Cases Reported to theMassachusetts Regional Center for Poison Control and Prevention for Patients Aged 0 to 19 Years, 2009-2016
Characteristic
Cases, No. (%)
Cannabis Single-Substance (n = 98) Cannabis-Involved Polysubstance (n = 120) All Cannabis-Involved (N = 218)
Sex
Female 47 (48.0) 39 (32.5) 86 (39.4)
Male 51 (52.0) 81 (67.5) 132 (60.6)
Age, y
0-4 19 (19.4) 3 (2.5) 22 (10.1)
5-9 2 (2.0) 2 (1.7) 4 (1.8)
10-14 8 (8.2) 6 (5.0) 14 (6.4)
15-19 69 (70.4) 109 (90.8) 178 (81.7)
Route of exposure
Inhalation/nasal 50 (51.0) 103 (85.8) 153 (70.2)
Ingestion 46 (46.9) 8 (6.7) 54 (24.8)
Inhalation/nasal/ingestion 0 2 (1.7) 2 (0.9)
Rectal 1 (1.0) 0 1 (0.5)
Unknown 1 (1.0) 7 (5.8) 8 (3.7)
Intention of exposure
Intentional, abuse and misuse 62 (63.3) 77 (64.2) 139 (63.8)
Intentional, suspected suicide 0 30 (25.0) 30 (13.8)
Intentional, unknown 3 (3.1) 4 (3.3) 7 (3.2)
Unintentionala 25 (25.5) 6 (5.0) 31 (14.2)
Other, malicious 4 (4.1) 0 4 (1.8)
Other or contamination, sampling 3 (3.1) 0 3 (1.4)
Adverse reaction, drug 0 1 (0.8) 1 (0.5)
Unknown 1 (1.0) 2 (1.7) 3 (1.4)
Medical outcome
Death 0 0 0
Major 1 (1.0) 3 (2.5) 4 (1.8)
Moderate 34 (34.7) 66 (55.0) 100 (45.9)
Minor 20 (20.4) 34 (28.3) 54 (24.8)
None 7 (7.1) 4 (3.3) 11 (5.0)
Unable to follow, judged potentially toxic 30 (30.6) 9 (7.5) 39 (17.9)
Not followed, minimal or unrelated 6 (6.1) 4 (3.3) 10 (4.6)
a Unintentional exposure category includes general, environmental, misuse, and unknown.
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importance, 21 (18%) as cases where cannabis ingestion likely had no clinical significance, and 14
cases (12%) as unclear. In cases in whichmedical toxicologists judged that cannabis had a substantial
impact on the clinical presentation, the other substances most frequently ingested were alcohol
(n = 22 [26%]), MDMA (n = 8 [9%]), alprazolam, a benzodiazepine sold as Xanax (n = 7 [8%]), and
preparations containing dextromethorphan (n = 6 [7%]).
The incidence for all cases involving cannabis for the 4 years before and after MMLwas 1.3 per
100000 population and 2.2 per 100000 population, respectively (IRR, 1.7; 95% CI, 1.2-2.2). The
incidence of cannabis single-substance cases was 0.4 per 100000 population before MML and 1.1
per 100000 population after (IRR, 2.2; 95% CI, 1.5-3.9), a 114% increase (Table 2). The incidence of
cannabis-involved polysubstance cases was 0.8 per 100000 population before MML and 1.0 per
100000 population after (IRR, 1.2; 95% CI, 0.9-1.8).
When stratified by age, the incidence of both single-substance and polysubstance cannabis
cases was highest for teenagers aged 15 to 19 years (Table 2). The incidence rate more than doubled
from before MML to after for this age group (IRR, 2.11; 95% CI, 1.24-3.66). This finding was consistent
with increases in incidence for the other age groups, although the IRRs for other age groups did not
reach statistical significance, likely owing to limited power from the small numbers of cases.
Over time and across age groups, most cannabis-related calls involved dried plant material.
Among children aged 0 to 4 years, compared with the time before MLL, a statistically significant
increase was observed in the incidence of exposures to edible products after MML (Figure). Among
teenagers aged 15 to 19 years, a statistically significant increase was observed in the incidence of
exposures to concentrated products and an increase in edible product exposures that was at the
significance threshold was found (P = .05).
The proportion of RPC cases due to cannabis (as a single substance) increased for all of the
youngest children (0-4 years) from 6 to 13 cases, and for teenagers (10-19 years) from 23 to 54 cases
after MML compared with those in the prior period (Table 3). Although cannabis exposures
represented a small proportion of the cases handled by the RPC—0.15% of the overall cases for
children and teenagers aged 0 to 19 years—the proportion doubled for each age group after MML.
Discussion
This analysis of RPC-reported cannabis exposures reveals a significant increase in the overall
incidence of pediatric exposures after MML in Massachusetts. The increase occurred despite the
cannabis product packaging being designed to be difficult for young children to open, being
unappealing to the youth, and requiring warning labels instructing that the product be kept away
from children.
Our study also highlights the fact that, in addition to concerns about unintentional cannabis
ingestion among young children, adolescents aged 15 to 19 years are experiencing negative cannabis-
related consequences that result in health care contacts via the poison control system. These
Table 2. Pediatric Cannabis Exposure Calls to theMassachusetts Regional Center for Poison Control and Prevention Before vs AfterMML
Age Group, y
No. of Calls (Incidence per 100 000 Population)











After vs Before MML,
IRR (95% CI)
All, 0-19 29 (0.4) 69 (1.1) 2.4 (1.5-3.9) 54 (0.8) 66 (1.0) 1.2 (0.9-1.8)
0-4 6 (0.4) 13 (0.9) 2.2 (0.8-7.0) 0 (0.0) 3 (0.2) NCa
5-9 0 (0.0) 2 (0.1) NCa 0 (0.0) 2 (0.1) NCa
10-14 1 (0.1) 7 (0.4) 7.1 (0.9-321.3) 4 (0.2) 2 (0.1) 0.5 (0.1-3.6)
15-19 22 (1.2) 47 (2.6) 2.2 (1.3-3.8) 50 (2.7) 59 (3.2) 1.2 (0.8-1.8)
Abbreviations: IRR, incidence rate ratio; MML, medical marijuana legalization; NC, not
calculated.
a The IRR cannot be calculated when incidence is 0 cases.
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findings are consistent with findings from other states and the continued observation of the
unintended consequences of MML and its influence on the pediatric population.7 Follow-up studies
should assess whether Massachusetts, like Colorado andWashington, may see a continuing increase
in pediatric cannabis exposure cases as implementation of commercial, adult-use cannabis sales
continues. States that have not revised their cannabis laws do not appear to be experiencing
increases in cannabis exposures.19
Figure. Regional Center for Poison Control and Prevention–Reported Pediatric Single-Substance Cannabis Exposure Cases by Product Type 4 Years Before vs After














































































a Indicates a statistically significant change in the percentage of all Regional Center for Poison Control and Prevention calls from before to after MML.
Table 3. Proportion of Pediatric Regional Center for Poison Control and Prevention Cases Involving Cannabis Before vs AfterMML inMassachusetts
Age Group, y
No. of Cannabis Cases (% of All Massachusetts RPC Cases)













All, 0-19 29 (0.04) 69 (0.10) <.001 54 (0.07) 66 (0.10) .07
0-4 6 (0.01) 13 (0.03) .05 0 3 (0.01) .10
5-9 0 2 (0.02) .22 0 2 (0.02) .22
10-14 1 (0.01) 7 (0.11) .03 4 (0.06) 2 (0.03) .47
15-19 22 (0.25) 47 (0.57) <.01 50 (0.58) 59 (0.72) .27
Abbreviations: MML, medical marijuana legalization; RPC, Regional Center for Poison
Control and Prevention.
a P values from χ2 tests or Fisher exact test when cell sizes were less than 5.
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Medical outcomes of single-substance exposures were generally moderate to minor, but the
increasing prevalence of exposures to concentrated and edible cannabis products and decrease in
exposures to plant material is concerning because of the increased potency of these product types.
Prior studies have been limited in examining product formulations prior to 2010 because a single
generic product code for marijuana was used until that time. In addition, the number of codes was
expanded in 2014 to include vaping products and in 2016 to include edibles as products available in
legal markets. We overcame this limitation by having trained RPC personnel recode the data to use
the new codes. Our finding that RPC-reported exposures to edible and concentrated cannabis
products increased after MML is consistent with data from other states.5 This outcome is concerning
considering recent evidence regarding associations between edible and concentrated cannabis and
acute psychiatric and emergency department visits.20
There are several specific regulations that Massachusetts has recently adopted in the context of
legalization for adult use that may help reduce cannabis poisoning in youth, including (1) laws
requiring locked storage of more than 28 g (1 oz) of marijuana; (2) regulations requiring that cannabis
packaging be in compliance with the US Consumer Product Safety Commission’s poison prevention
packaging requirements13; and (3) fines or imprisonment for providing cannabis products or
accessories to underaged individuals.21 In-home cannabis storage practices and fines for diversion to
minors should be tracked to evaluate the extent to which these protections are implemented.
Further, multistate studies that examine variation in marijuana regulations like those outlined above
are needed to help determine the influence of specific policies and regulations and develop
evidence-based recommendations.
Limitations
This study has limitations. First, it cannot be discerned whether our finding of increased cannabis
exposure calls to the RPC after MML is the result of increased exposures or reduced stigma for
parents, caregivers, or adolescents calling to report such an exposure or going to the hospital.22
However, cannabis possession has been decriminalized in Massachusetts since 2010; consequently,
during most of the prelegalization period, admitting marijuana use or possession would not have
incurred legal ramifications. It is possible that policy changes or population-level trends not
measured in this analysis contribute to the observed changes in the outcomes. Small numbers may
have limited our power to detect statistically significant changes. The assessment of cannabis
exposure is generally self-reported in RPC data and therefore potentially subject to recall bias or
incomplete ascertainment of cases. Exposures may not be verified by laboratory testing. While this
study is representative of Massachusetts and echoes findings from other states, trends in pediatric
cannabis exposures may differ in other states.
Despite these limitations, this study adds to the evidence base regarding the potential influence
of marijuana-related policies on youth. It will be important for Massachusetts and other states to
continue tomonitor poison center calls as cannabis policies are implemented. Suchmonitoring could
be facilitated by creating state or national databases inwhich information about and package images
for specific cannabis products involved in acute health care visits can be uploaded or by adding such
information to an existing resource, such as the national Toxicology Investigators Consortium
database.23 Creation of such databases could help regulators and public health officials understand
any emerging patterns in problems from specific products or product types.
Conclusions
In Massachusetts, the incidence of pediatric single-substance cannabis cases and the proportion of
all pediatric cannabis-related calls to the RPC more than doubled after MML compared with before
MML. States implementing medical marijuana policies should ensure that regional poison centers
and other health care facilities are adequately prepared to respond to such increases. While it is
encouraging that cannabis-related RPC calls were relatively uncommon for very young children, who
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may be unintentionally ingesting cannabis products owned by their parents, older siblings, or
caregivers, continued efforts are needed to help keep cannabis away from them. It is also imperative
to sustain efforts to help teenagers avoid cannabis use.
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